MedTrace Logo

New Preclinical and Clinical Approaches to Mesothelioma

NCT06536179 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-08-02

No results posted yet for this study

Summary

This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.

Conditions

Sponsors & Collaborators

  • Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

    collaborator NETWORK

  • Marco Emilio Bianchi

    lead OTHER

Principal Investigators

  • Marco Bianchi, Professor · IRCCS Ospedale San Raffaele

  • Vincenzo Sforza, MD · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-25
Primary Completion
2025-07-25
Completion
2027-01-25

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536179 on ClinicalTrials.gov